Last Chance to Save $200!
Prices Increase This Friday.
|
|
|
In just three weeks Fierce JPM Week will be returning to San Francisco on January 9-10th and a who's who in Pharma and Biotech will be coming together to share their experiences, insights and thoughts on the upcoming year's hottest topics.
Brought to you by the award-winning editors behind Fierce Pharma and Fierce Biotech, our 2024 program has two full days of insights covering the Inflation Reduction Act, biopharma M&A, advancements and challenges in gene therapy, IPOs, Oncology's next frontier and more! Don't miss this all-star lineup of speakers and join over 500 senior biotech and pharma executives at this one-of-a-kind event focused on learning, networking and connecting. Below is a snapshot of new speakers and can't-miss sessions you won't find anywhere else! VIEW THE AGENDA>> Register now and save $200 with the Advanced Rate! Prices increase this Friday and only 35 passes are left at this rate. Don't wait to secure your spot now at the lowest available price. |
|
|
Johanna Mercier Chief Commercial Officer Gilead |
| Marianne De Backer
Chief Executive Officer and Director
Vir Biotechnology, Inc. |
| Robert Plenge
EVP, Chief Research Officer, Head of Research
Bristol-Myers Squibb |
|
|
Daejin Abidoye
Vice President, Therapeutic Area Head Solid Tumor
AbbieVie |
| Issei Tsukamoto
SVP and Head of GlobalBusiness Development
Astellas Pharma Inc. |
| Elizabeth Naldi Jacob
Head of Oncology BD & Headquarters Transactions
Merck |
|
|
Chris McDonald
SVP and Global Head of Technical Operations
Kite Pharma |
| Morten Sogaard
President and Division Head of Research and Technical Operations
Astellas Gene Therapies |
| Kate Haviland
Chief Executive Officer
Blueprint Medicines |
|
|
- Crossovers, Megarounds and IPOs: Biotechs Always Find a Way
- Exploring the Inflation Reduction Act: Pharma's Legal Battles and the Future of Innovation
- A Look at Biopharma M&A and Shifting Deal Dynamics
- Advancements and Challenges in Cell & Gene Therapy Manufacturing
- Oncology's Next Frontier: ADCs, Radiopharma and the Future of Cancer Treatment
- Revolutionizing Healthcare: The Impact of AI Disruption in Clinical Trials
|
Exclusive Executive Interviews by the Fierce Editorial Team: |
- Johanna Mercier, Chief Commercial Officer, Gilead
- Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis
- Shehnaaz Suliman, Chief Executive Officer, ReCode Therapeutics
- Marianne De Backer, Chief Executive Officer, Vir Biotechnology
- Robert Plenge, EVP, Chief Research Officer, Head of Research, Bristol-Myers Squibb
- Jürgen Eckhardt, EVP, Head of Leaps by Bayer and Head of Pharmaceuticals Business Development, Licensing & Open Innovation, Bayer Pharmaceuticals
|
|
|
Limited Partnership Opportunities Left! |
|
|
| | | 2 Days Great Content and Opportunities to Network |
|
|
| Position your company as a thought leader, promote your brand and engage with leading Biotech and Pharma Executives. Contact us today to learn why Fierce JPM Week is the right show for you! |
|
|
Thank You to Our Partners |
|
|
If you no longer wish to receive promotion on this event, simply unsubscribe.
Refer to our Privacy Policy.
Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017 Contact Us
© 2022 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. |
|
|
|
